TMDX
NASDAQTransMedics Group Inc.
Price$69.72+2.52 (+3.74%)
01:30 PM07:45 PM
News · 26 weeks47+33%
2025-12-072026-05-31
Mix2790d
- Insider11(41%)
- Other7(26%)
- SEC Filings6(22%)
- Earnings2(7%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form SD filed by TransMedics Group Inc.SD - TransMedics Group, Inc. (0001756262) (Filer)
- INSIDERDirector Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Raines Merilee was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Weill David was granted 2,922 shares, increasing direct ownership by 24% to 15,056 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Lovell Stephanie was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Tobin James R was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDERDirector Kania Edwin was granted 2,922 shares, increasing direct ownership by 1% to 263,732 units (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- INSIDEROfficer Forsyth Matthew S. was granted 15,409 shares (SEC Form 4)4 - TransMedics Group, Inc. (0001756262) (Issuer)
- SECSEC Form 8-K filed by TransMedics Group Inc.8-K - TransMedics Group, Inc. (0001756262) (Filer)
- PRTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 19, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 37,367 shares of its common stock and an aggregate of 24,848 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants included stock options to purchase 23,171 shares of TransMedics' common stock and 15,409 restricted stock units granted to Matthew S. Forsyth, the Co
- PRTransMedics to Present at the William Blair 46th Annual Growth Stock ConferenceANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The TransMedics management team will present beginning at 2:20 p.m. ET/ 1:20 p.m. CT. A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website
- SECSEC Form DEFA14A filed by TransMedics Group Inc.DEFA14A - TransMedics Group, Inc. (0001756262) (Filer)
- ANALYSTTransMedics Group downgraded by OppenheimerOppenheimer downgraded TransMedics Group from Outperform to Perform
- SECSEC Form 10-Q filed by TransMedics Group Inc.10-Q - TransMedics Group, Inc. (0001756262) (Filer)
- SECTransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TransMedics Group, Inc. (0001756262) (Filer)
- PRTransMedics Reports First Quarter 2026 Financial ResultsANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2026. Recent HighlightsTotal revenue of $173.9 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025Net income of $7.3 million or $0.20 per fully diluted share in the first quarter of 2026Adjusted net income of $10.9 million or $0.30 per fully dilut
- PRTransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbHProposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across EuropeANDOVER, Mass., April 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it has entered into a definitive agreement to invest in PAD Aviation, a premier Germany-based private aviation operator.
- PRThe Quiet Rule Change Tilting $10B Toward Medtech's Most Validated PlatformsIssued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, April 29, 2026 /CNW/ -- Equity-Insider.com News Commentary – Here's the quiet shift in medtech right now: the global medical imaging market is on track to grow from $41.64 billion in 2024 to $67.87 billion by 2034[1], and capital has stopped chasing every shiny promise. That pressure got real in April, when the FDA advanced its real-world evidence framework for medical devices[2], lining regulators and payers up around documented performance instead of trial-stage pitches. Five names keep showing up in that conversation: VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Senseonics (NASDAQ:SENS), TransMedics Group (NASDAQ:TMDX),
- PRTransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual MeetingUnveils New Controlled Hypothermic Organ Preservation System (CHOPS) to Expand its Product Portfolio and to Facilitate Enrollment in Control Arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung Clinical TrialsANDOVER, Mass., April 23, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, is today providing an update on its ongoing clinical programs at the International Society of Heart and Lung Transplantation (ISHLT) 2026 Annual Meeting in Toronto, Canada. At the meeting, TransMedics will unveil its new controlled, active cooling preser
- PRTransMedics to Report First Quarter 2026 Financial Results on May 5, 2026ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ:TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic c
- SECSEC Form DEFA14A filed by TransMedics Group Inc.DEFA14A - TransMedics Group, Inc. (0001756262) (Filer)
- SECSEC Form DEF 14A filed by TransMedics Group Inc.DEF 14A - TransMedics Group, Inc. (0001756262) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TransMedics Group Inc.SCHEDULE 13G/A - TransMedics Group, Inc. (0001756262) (Subject)
- INSIDERSEC Form 3 filed by new insider Forsyth Matthew S.3 - TransMedics Group, Inc. (0001756262) (Issuer)
TMDX FAQ
7 questionsWhat does TransMedics Group Inc. do?
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state...Where does TMDX stock trade?
TransMedics Group Inc. (TMDX) is listed on NASDAQ.What sector and industry is TMDX in?
TransMedics Group Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did TransMedics Group Inc. go public?
TransMedics Group Inc. (TMDX) completed its IPO in 2019.What are analysts saying about TMDX?
TransMedics Group Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2026-05-06.What companies are similar to TMDX?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare TMDX side-by-side with any of them on Quantisnow.How can I track TMDX on Quantisnow?
Quantisnow aggregates TransMedics Group Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TMDX to receive live email and push alerts on every new disclosure.